Cheminformatics Driven Development of Novel Therapies for Drug Resistant Prostate Cancer

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Androgen receptor (AR) is crucial in prostate cancer (PCa) development and progression.
• Castration-resistant prostate cancer (CRPC) remains a significant clinical challenge due to acquired resistance to antiandrogen therapies.
• Current antiandrogens targeting the AR ligand-binding domain face limitations due to resistance mechanisms.

Purpose of the Study:

• To discuss recent advancements in small molecule inhibitors targeting AR.
• To introduce novel AR inhibitors designed to circumvent resistance mechanisms.
• To explore inhibitors targeting functional sites distinct from the AR ligand-binding domain.

Main Methods:

• Cheminformatics techniques were employed for the design of novel AR inhibitors.
• Inhibitors were designed to target specific AR functional sites, including AF2, BF3, and DNA-binding domains (DBD).
• The study reviews strategies for developing small molecules that inhibit AR activity through non-canonical binding sites.

Main Results:

• New classes of AR inhibitors targeting AF2 and BF3 functional sites and DBD domains have been developed.
• These novel inhibitors show promise in overcoming various AR-dependent resistance mechanisms.
• Targeting distinct AR sites offers a strategy to circumvent resistance to conventional antiandrogens.

Conclusions:

• Novel AR inhibitors targeting AF2, BF3, and DBD domains represent a promising therapeutic strategy for PCa, including CRPC.
• These inhibitors are designed to overcome resistance associated with current antiandrogen therapies.
• Targeting distinct AR functional sites is a viable approach to develop next-generation therapies for prostate cancer.